Kynexis Doses First Patient in Phase 2 Trial of KYN-5356 for Cognitive Impairment Associated with Schizophrenia

Kynexis, a clinical-stage biotechnology company focused on precision therapeutics for brain diseases, announced that the first patient has been dosed in ...

October 01, 2025 | Wednesday | News
VERAXA Biotech and Secarna Pharmaceuticals Form Strategic Alliance to Develop Next-Generation Antibody Oligonucleotide Conjugates

VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH,...

October 01, 2025 | Wednesday | News
Amneal Pharmaceuticals Submits BLA for Omalizumab Biosimilar to XOLAIR®, Developed with Kashiv BioSciences

Amneal Pharmaceuticals, Inc.announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a propos...

September 30, 2025 | Tuesday | News
Concept Life Sciences Expands Integrated Drug Discovery Facilities in High Peak

Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences and pharma industry, announces the official openin...

September 30, 2025 | Tuesday | News
Philips Unveils Next-Generation CT and Helium-Free MR Systems to Transform Precision and Sustainability in Radiation Therapy

New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value Philips deb...

September 29, 2025 | Monday | News
Sen-Jam and KVK Tech Complete NDA-Ready CMC Package and Submission Batches for SJP-002C

Completion of submission batches and NDA-ready CMC package strengthens regulatory foundation for upcoming Phase 2b/3 trials and underscores Sen-Jam's lea...

September 29, 2025 | Monday | News
ME Therapeutics Secures U.S. Patent for Lead G-CSF Antibody Candidate to Advance Cancer Immunotherapies

ME Therapeutics Holdings Inc. a publicly listed biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased ...

September 29, 2025 | Monday | News
Avant Technologies, Inc. Bolsters Strategic Vision with Targeted Biotech Partnerships for Innovative Cell-Based Therapies

Avant Technologies Inc. announced a pivotal evolution in its business direction, emphasizing strategic partnerships through joint ventures and licensing ...

September 26, 2025 | Friday | News
European Commission Approves Lilly’s Kisunla™ (donanemab) for Early Symptomatic Alzheimer’s Disease

Approved for use in the earliest symptomatic stages, Kisunla is the only once-monthly amyloid plaque–targeting therapy with evidence supporting tre...

September 26, 2025 | Friday | News
Sanofi Ventures Secures $625M Boost, Expanding Assets to $1.4B

The fund will remain focused on Sanofi's key areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging...

September 25, 2025 | Thursday | News
Ncardia Launches First iPSC-Derived Non-Human Primate Cardiomyocytes for Translational Cardiac Research

-Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment,  announced the launch of Ncyte® NHP-C vCardiomyo...

September 24, 2025 | Wednesday | News
Remedium Bio and Eli Lilly Enter Multi-Target Gene Therapy Collaboration in Type 2 Diabetes and Obesity

Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. ("Remedium"), has entered into a multi-target research and...

September 24, 2025 | Wednesday | News
Illumina Expands Global CDx Partnerships to Advance KRAS-Targeted Precision Oncology

Illumina Inc. (NASDAQ: ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the T...

September 24, 2025 | Wednesday | News
Angelini Pharma and South Korea’s Sovargen Sign Global Option Agreement for First-in-Class Brain Health Therapy SVG105

Angelini Pharma, part of the privately owned Angelini Industries, and Sovargen, a South-Korean biotechnology company, announced today that they signed an...

September 23, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close